Mortgage rates for 30-year fixed loans rose to 7.12%, the highest since 2024, causing a 1.5% drop in total loan applications. Refinancing requests fell 3% and were 62% lower than last year, hitting the lowest level since February 2025. Meanwhile, more borrowers are choosing adjustable-rate mortgages (ARMs), which now account for 9.8% of applications, as their rates are over 1% lower than fixed loans. The higher rates are cooling the housing market, with buyers and homeowners seeking cheaper loan options amid rising costs.
Mortgage riskier loans data provide context for readers. As of Sep 23, 2026 17:51 WIB, 53 of 83 Financials-sector US stocks on Pluang rose, 25 fell. Nomura Holdings Inc (NMR) rose 7.03% to USD 10.66 with 66% buy orders. Raymond James Financial (RJF) gained 3.64% at USD 165.19, fully bought. Deutsche Bank AG (DB) fell 2.69% to USD 36.55, fully bought. This snapshot shows mixed investor sentiment in financial stocks.
A Snap insider has sold 20,000 shares as the company's stock has declined by 27% over the last year. This insider sale may signal concerns about the stock's near-term prospects or a personal decision to liquidate holdings. Investors should watch for ...
Dogecoin (DOGE) has gained over $171 million in market cap recently, driven by a broader altcoin rally. Three AI platforms—Grok, Gemini, and ChatGPT—forecast an average price increase to $0.1082 by October 1, 2026, suggesting an 8.82% rise from curre...
Analyst Ali Martinez identifies a bullish reversal for the altcoin SUI following an 83% drop from previous highs. Three key weekly indicators—the Tom DeMark Sequential, SuperTrend, and Parabolic SAR—have flipped to buy signals, confirming a potential...
Micron's stock has risen 18.17% this week, closing at $1,096.16, with Wall Street analysts divided on price targets ranging from hold to $2,000 ahead of its September 30 earnings report. The company expects $50 billion in revenue and $31.00 non-GAAP ...
Bio-Techne shareholders have voted to approve the acquisition agreement with Merck KGaA, marking a key step toward completing the merger. The deal, which combines Bio-Techne's life science tools with Merck's global capabilities, aims to enhance suppo...
